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Abstract
Background: Missense mutations in three different genes encoding amyloid-b precursor protein, presenilin 1 and
presenilin 2 are recognized to cause familial early-onset Alzheimer disease. Also duplications of the amyloid
precursor protein gene have been shown to cause the disease. At the Dept. of Geriatric Medicine, Karolinska
University Hospital, Sweden, patients are referred for mutation screening for the identification of nucleotide
variations and for determining copy-number of the APP locus.
Methods: We combined the method of microsatellite marker genotyping with a quantitative real-time PCR analysis
to detect duplications in patients with Alzheimer disease.
Results: In 22 DNA samples from individuals diagnosed with clinical Alzheimer disease, we identified one patient
carrying a duplication on chromosome 21 which included the APP locus. Further mapping of the chromosomal region
by array-comparative genome hybridization showed that the duplication spanned a maximal region of 1.09 Mb.
Conclusions: This is the first report of an APP duplication in a Swedish Alzheimer patient and describes the use of
quantitative real-time PCR as a tool for determining copy-number of the APP locus.
Background
Missense mutations in three different genes encoding
amyloid-b precursor protein [1] (APP, [MIM 104760]),
presenilin 1 [2] (PSEN1, [MIM 104311]) and presenilin 2
[3] (PSEN2, [MIM 600759]) are recognized to cause
familial early-onset Alzheimer disease (EO-AD; [MIM
104300]). The mutations are known to functionally
change the proteolytic processing of the APP protein,
which leads to an increased Ab42/Ab40 ratio and
increased Ab-deposition in the brain. In addition to
nucleotide variations, an increased dosage of the APP
gene is also known to cause Alzheimer disease (AD) [4].
This is in agreement with previous observations that
patients with Down syndrome (DS, trisomy 21, [MIM
190685]), who carry an extra copy of the APP gene,
develop AD early in age [5-7]. Duplication of the APP
locus has been detected in six unrelated French families
[4,8], two Dutch families [9], one Finnish family [10], five
families from a UK screen [11], and in two Japanese
families [12]. The reported size of APP duplications
range from 0.5 to 6.5 Mb, with the exception of an
extended discontinuous duplication identified to be 15.5
Mb plus 1.5 Mb found in the UK screen [11]. Notably, a
study on EO-AD cases from Finland and Sweden failed
to identify duplications of the APP locus in a total of 141
AD patient, and concluded that the prevalence in these
populations are low [13].
At the Dept. of Geriatric Medicine, Karolinska University
Hospital, Sweden, patients are referred for mutation
screening at the Genetic Unit for the identification of
nucleotide variations and for determining copy-number of
the APP locus. During the period between April 2008 and
June 2010, a total number of 22 patients with clinical AD
were referred for mutation screening, and the first finding
of an APP duplication in a Swedish patient was made. The
duplication was identified by analysis of microsatellite
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by array-based comparative genome hybridization (aCGH).
The duplication covers 1.09 Mb on chromosome 21q21,
including the entire gene for APP. In this cohort of patients
referred for mutation screening, the genomic duplication
occurs at a frequency of 4.5% (1/22). This shows the
importance of continued screening for APP locus duplica-
tion in Swedish AD patients, in parallel with sequencing
efforts for the detection of nucleotide variations.
Methods
Patient and family history
Twenty-two patients were referred for mutation screening
in the genes APP, PSEN1, PSEN2 at the Genetics Unit as
part of the clinical investigation at the Dept of Geriatric
Medicine, Karolinska University Hospital, Sweden. We
made a subjective classification of the 22 subjects into four
groups: early onset familial AD (EO-FAD); familial AD
(FAD); possible familial AD (poss. FAD) and AD (Addi-
tional file 1). Ten cases were classified as “EO-FAD”,
where an autosomal dominant history of early onset (≤65
years of age) in at least three affected family members in
two generations were found. Four of the cases were classi-
fied as “FAD”, where there was at least three affected
family members in two generations but where the onset in
one of the family members was >65 years of age, and thus
not fulfilling the criteria for early-onset. Six of the subjects
were categorized as “possible FAD”,s i n c et h en u m b e ro f
identified family members with AD were not sufficient to
definitively conclude the nature of inheritance. Finally, two
patients were referred for mutation screening on the basis
of autopsy-confirmed severe cerebral amyloid angiopathy
(CAA) or because of an extreme early-onset, <30 years of
age and classified as “AD”.
The study was performed in accordance with the Hel-
sinki Declaration, with informed consent and approval
from the local ethics committee (Stockholm).
DNA samples
Genomic DNA was extracted from peripheral blood using
the manufacturer’s protocol (Gentra Purgene Blood kit,
Qiagen, Sweden). A DNA sample from an individual with
t r i s o m y2 1( T 2 1 )w a su s e da sap o s i t i v ec o n t r o lf o rt h e
microsatellite marker analyses and for the APP copy-num-
ber assay (Coriell Cell Repositories Camden, New Jersey,
USA, (Catalog ID: GM02767).
DNA sequencing
Sequencing reactions were performed using BigDye
®
Terminator v3.1 Cycle sequencing kit (Applied Biosys-
tems, Carlsbad, California, USA) followed by capillary
electrophoresis on a ABI 3100 Genetic Analyzer (Applied
Biosystems, Carlsbad, California, USA). Primers and PCR
conditions are available on request.
Microsatellite marker analysis
DNA from patients, D01-D22, were amplified with pri-
mers for microsatellite marker GDB:188463 (D21S265),
located 330 kb centromeric to the APP gene, and for
GBD:196999 (APP-dint), located in intron 1 of APP [4].
Fluorescent PCR-products were separated by capillary
electrophoresis on an ABI 3100 instrument (Applied Bio-
systems, Carlsbad, California, USA) and the electrophero-
grams were analyzed by using the GeneMapper 3.7
software (Applied Biosystems, Carlsbad, California, USA).
The area under each allele’s major peak was determined
and the ratio for the two different allele-areas for a marker
was calculated to evaluate copy-number variation. A
balanced copy-number of two was scored for ratios
between 0.8 and 1.4, whereas ratios less than 0.65 or
greater than 1.8 were used to define samples with three
alleles.
Amplification with Taq-polymerase can result in so-
called stutter-peaks when two alleles only differ by two
nucleotides in size [14]. Therefore, markers with alleles
that differ by two nucleotides were allowed to have ratios
between 1.4 - 1.8 and still score as a normal copy-number.
Mono-allelic markers yielding only one peak were not
informative for indicating copy-number.
Copy-number assay
Quantitative real-time PCR was performed with the Taq-
man
® copy-number assay method according to the manu-
facturer’s protocol (Applied Biosystems, Carlsbad,
California, USA). The assays amplify target-regions within
the APP locus in exon 1 (Assay ID: Hs00569527_cn), exon
7 (Assay ID: Hs02339796_cn), and in exon 17 (Assay ID:
Hs00525904_cn). Additional assays amplify regions in clo-
sely located genes; MIR155HG (Assay ID: Hs040
70445_cn), ATP5J (Assay ID: Hs02552822_cn), CYYR1
(Assay ID: Hs01271635_cn), and ADAMTS1 (Assay ID:
Hs00609065_cn) (Additional file 2). Briefly, target assay-
primers with a FAM-dye labeled probe and the calibrator
RNase P-primers with a VIC-dye labeled probe, were used
together in a duplex real-time PCR-reaction. The cycle
threshold (Ct)-value at log-linear phase was used to calcu-
late delta Ct-valuessample (dCtsample) between the target
assay and calibrator assay (CtAssay -C t Calibrator = dCtsample).
The mean from tetraplicates of delta Ctsamples from each
sample DNA (D01-D22, and T21), was used for calculat-
ing relative copy-number normalized to the mean dCt-
value of the trisomy 21 control DNA (T21) by the equa-
tion: 2^
(dCtT21-dCtsample)*3.
Comparative genome hybridisation
The commercially available 180 K oligonucleotide cata-
log design (design ID 022060, Agilent Technologies,
Palo Alto, CA, USA) with complete genome coverage
and overall median probe spacing of 13 kb was used.
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turer’s protocol with minor modifications. Briefly,
patient DNA and a gender-matched control (Promega,
Wisconsin, USA) were labeled by random priming
(Enzo life sciences, New York, USA) with Cy3-dUTP
and Cy5-dUTP respectively. After denaturing the probe
and pre-annealing with 50 μg of Cot-1 DNA (Invitrogen,
California, USA), hybridization was performed at 65 °C
with rotation for 24 hours. The array was scanned with
the Agilent microarray scanner (Palo Alto, CA, USA).
Feature Extraction (v10.2) and DNA Analytics (v4.0)
software packages (Agilent technologies) were used for
analysis and duplication breakpoints were determined by
visual inspection of the numerical normalized log2 ratio
values in the table-view of the DNA analytics software
package. The genomic positions refer to the Human
Genome Build 36.1 (UCSC Genome Browser, assembly
March2006).
Results
Twenty-two patients were referred for mutation screen-
ing in the genes APP, PSEN1 and PSEN2 during the
period of April 2008 to June 2010 at the Dept. of Geria-
tric Medicine, Karolinska University Hospital, Sweden.
The screening involved genomic sequencing of exons
16-17 in APP,e x o n s2 - 1 2i nPSEN1,e x o n s3 - 7a n d
exon 12 in PSEN2. No variation in APP was detected in
any of the 22 DNA samples. In contrast we identified
polymorphic SNPs in both PSEN1 and PSEN2.P o l y -
morphic SNPs in PSEN2 were frequently detected and,
in addition to the seven previously reported polymorph-
isms, we also found a novel variation at IVS6 +91 (G>C;
GRCh37:1:227075950) (see Additional file 3 and Addi-
tional file 4). The functional implication on pathogenesis
was tested by in silico methods. We were not able to
detect a functional impact of the variation, neither by
splice-prediction analysis nor by examining conservation
between species (Additional file 4). Taken together, our
sequencing effort did not find variations that could
explain the diseased state of the patients.
To address the possibility of a duplication of APP,t w o
microsatellite markers GDB:196999, (APP-dint), and
GDB:188463, (D21S265) were PCR amplified with fluores-
cent primers. When analyzing the 22 DNA samples,
16 were heterozygous (polymorphic) for the marker
GDB:196999 and 20 were heterozygous for marker
GDB:188463. In our set-up, the size of alleles for marker
GDB:196999 ranged from 163 bp to 191 bp, and the size
of alleles for GDB:188463 ranged from 241 bp to 255 bp
(Table 1). The allele-ratio calculated for marker GDB:
196999 was between 0.8 - 1.4 indicating a balanced diploid
copy-number, except for sample D08 (Table 1). In sample
D08, the areas for alleles 174 bp and 189 bp for GDB:
196999 had a ratio of 2.24 (17752/7932) indicating an
unbalanced 2:1 copy-number (Figure 1). Six of the indivi-
duals were monoallelic for the marker. When calculating
the allele-ratios for marker GDB:188463 in the sample-set,
thirteen out of 22 DNA samples had ratios between 0.8 -
1.4. Seven samples had ratios between 1.4 - 1.8 and five of
these samples had alleles that only differed by two nucleo-
tides in size (D03, D18, D20 - 22); thereby leading to infla-
tion of the area of the shorter allele (Table 1). The ratios for
D13 and D15 were slightly higher than 1.4 and monoallelic
for GDB:196999. Two samples were monoallelic for marker
GDB:188463 (D08 and D16) and therefore did not generate
any allele ratios. As an example, in Figure 1, DNA sample
D07 carries two alleles for both markers, GDB:196999 and
GDB:188463, and the calculated ratio for alleles GDB:
196999-174 and GDB:196999-189 was 1.24, (3213/2582),
indicating a balanced copy-number of two. Similarly, the
ratio for the alleles of GDB:188463 is calculated to be 1.02
(902/883) for sample D07. Also illustrated, sample D08 was
not informative for marker GDB:188463 since it only car-
ried one allele, the 247 bp (Figure 1b), but an unbalanced
copy-number are visible as the ratio, 2.24 (17752/7932), for
the alleles of marker GDB:196999. Furthermore, sample
D09 was not informative for marker GDB:196999 since it
only carried one allele (189 bp), but could be examined at
the GDB:188463 marker, with a ratio of 1.08 (6683/6190)
(Figure 1b). The control DNA carrying trisomy 21 dis-
played three alleles for both examined markers (Figure 1a-
b). The finding indicated that sample D08 carries a duplica-
tion of the genomic locus for marker GDB:196999.
To confirm the APP copy-number detected by microsa-
tellite analysis, we used a quantitative real-time PCR
method (The TaqMan Copy Number Assay, Applied Bio-
systems Carlsbad, California). The number of copies was
determined by comparing patient DNA with a positive
control DNA from a subject with trisomy 21 (copy-num-
ber of three). Three different exons of the APP gene were
amplified by a duplex real-time PCR method for exon 1,
exon 7, and exon 17. By calculating the relative copy-num-
ber, samples D07 and D09 were found to be diploid for all
three amplicons (Figure 2, top). In contrast, sample D08
was found to have a copy-number value of three for all
three amplicons. Thus, the copy-number assay confirmed
the presence of three copies detected by the microsatellite
analysis for D08. All the other DNA samples were deter-
mined by the copy-number assay to have relative copy-
number values of 1.52-2.33, indicating a copy-number of
two (Table 1). Noteworthy, the copy-number assay for
samples D13 and D15 showed no variation in any of the
exons examined and thus could be determined to carry
normal number of the APP gene.
We wanted to address how far the duplication extended
into the flanking chromosomal regions and if any neighbor-
ing genes were duplicated in addition to APP. For this pur-
pose, copy-number assays targeting the genes MIR155HG,
Thonberg et al. BMC Research Notes 2011, 4:476
http://www.biomedcentral.com/1756-0500/4/476
Page 3 of 9ATP5J, CYYR1,a n dADAMTS1 were analyzed (for loca-
tions see Additional file 2). The relative copy-number for
samples D07 and D09 was two for all of the four investi-
gated genes (Figure 2 lower). The relative copy-number
values ranged from 1.78 (ATP5J, sample D07) to 2.15
(ATP5J, sample D09). The duplication established in sam-
ple D08 was determined to include the locus for the ATP5J
gene located centromeric as well as the locus for the
CYYR1 gene located telomeric of APP and the relative
copy-number for these two assays were close to three, (3.34
and 3.41 respectively) (Figure 2 lower). However, the dupli-
cation did not include the more distal gene MIR155HG,
located centromeric, or the gene for ADAMTS1 located
telomeric (Figure 2 lower) as indicated by the relative copy-
number values of 2.14 and 2.07 respectively. We could
therefore limit the duplication to a maximal region of 1.27
Mb on chromosome 21 between genomic position 25
868029 bp and 27 138783 bp (Build 36.1).
To fine-map the duplicated region, array-CGH was used
by hybridizing DNA sample D08 to a 180 k array covering
the APP locus. The method compares hybridization sig-
nals from the D08 DNA with a diploid control DNA. The
signal intensities were plotted against positions on the
chromosome and shows that the duplication covers a
region on chromosome 21 restricted to a maximum size
of 1.09 Mb within coordinates 25 950727 bp - 27 043885
bp, and to a minimum size of 1.01 Mb within coordinates
25 957532 bp - 26 971 366 bp (Figure 3). Thus, the array-
CGH confirms the presence of a genomic duplication
including the APP gene in sample D08.
Discussion
The genetic causes for EO-FAD are strongly linked to
three genes: APP, PSEN1,a n dPSEN2. The frequency in
which mutations in these genes contribute to EO-FAD is
reported to range from 17% to around 80% [15-18],
depending on the population examined, the sample size,
and the diagnostic criteria (for review see Avramopouls
2009) [19]. At the Dept. of Geriatric Medicine, Karolinska
University Hospital, Sweden, patients with a suspected
genetic cause of AD are referred for mutation screening
in the genes APP, PSEN1,a n dPSEN2. In addition to
using sequencing for mutation screening, we have devel-
oped a protocol for analyzing the copy-number of APP.
The protocol includes both a microsatellite analysis and a
copy-number assay. Here we report on the results from
Table 1 Copy-number determination in 22 AD patients referred for mutation screening
GDB:196999 (APPdint) GDB:188463 (D21S265) CNA-APP
alleles ratio alleles ratio E1 E7 E17
D01 185/189 1,34 243/253 1,03 2,17 2,01 2,18
D02 174/189 1,19 241/245 1,37 2,11 1,91 2,17
D03 174/189 1,18 245/247 1,57 1,93 1,87 2,07
D04 189/199 1,11 245/247 1,18 2,14 1,90 2,09
D05 174/189 1,27 245/249 0,92 2,16 2,01 2,05
D06 191 - 243/249 0,93 2,28 2,33 2,17
D07 174/189 1,24 249/253 1,02 2,00 2,04 2,08
D08 174/189 2,24 247 - 3,42 3,49 3,44
D09 189 - 241/253 1,07 2,03 2,06 2,12
D10 163/174 1,21 245/255 1,04 1,67 1,81 1,92
D11 174/189 1,00 247/255 1,19 1,78 2,23 1,92
D12 163/174 1,18 249/255 0,97 1,65 1,71 1,85
D13 189 - 247/251 1,45 1,90 1,83 2,06
D14 174/178 1,35 245/249 1,38 1,74 1,55 1,78
D15 189 - 249/253 1,53 2,15 2,01 1,95
D16 163/189 1,30 247 - nd nd nd
D17 189 - 241/247 1,24 1,52 1,63 1,71
D18 174/191 1,21 247/249 1,63 1,54 1,81 1,79
D19 178/189 1,33 247/255 1,12 1,54 1,58 1,63
D20 178/189 0,95 247/249 1,67 1,93 2,27 2,18
D21 189 - 247/249 1,73 1,92 2,22 2,30
D22 189/193 1,36 247/249 1,70 2,02 2,02 2,00
DNA samples are numbered D01-D22. From left; microsatellite-analysis for marker GDB:196999 (APP-dint) and GDB:188463 (D21S265). The column “alleles” for
each of the two markers gives the allele size in base-pairs. Also, for the two markers, and given in the column “ratio”, are the ratios between the peak-areas
under each alleles major peak. Relative copy-number values from the copy-number assays (CNA-APP) targeting APP-exon 1 (E1), exon 7 (E7) and exon 17 (E17).
The values in each column are calculated as relative to trisomy 21-DNA control and given as mean of tetraplicates. The abbreviation “nd” stands for not
determined. Bold figures indicate ratio and copy-number of samples with suspected copy-number variation.
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copy-number analyses of 22 AD patients referred for
mutation screening on the basis of their familial history
with the detection of an APP duplication in one of the 22
patients. The calculated duplication frequency found in
the present study depends on the number of samples
considered, i.e. when only the 10 EO-FAD patients are
included the frequency is 10%, and when including all 22
samples the frequency is 4.5%.
In contrast, our sequencing efforts did not identify any
nucleotide variations in the three genes that could
explain the diseased state. The low frequency of muta-
tions in the Swedish population is also notable in earlier
studies [20,21]. The mutations found so far in Swedish
patients are six in total, and includes two in APP [22,23]
and four in PSEN1 [20,24,25]. This finding strengthens
the notion that mutations in APP, PSEN1 and PSEN2
are less frequent in Swedish families than in the reports
on European EO-FAD. Significantly, 10 of the 22
patients had a family history with early-onset (≤ 65
year-of age), and an additional four of the patients came
from families with an autosomal dominant history of
AD.
The recognition of APP duplication as a genetic cause
for AD has raised the issue of to what degree it explains
familial EO-AD. Others have reported frequencies of
APP-duplications between 2.7% and 8% in familial cases
of AD [4,9,12]. This indicates that the contribution of
APP duplications as a cause for the disease is one third to
half of that from APP nucleotide missense mutations
[15]. A report on screening for APP duplication in 77
Swedish and 64 Finnish patients did not succeed in find-
ing any copy-number variations [13]. Again, this indi-
cated that frequencies of genetic variations may differ
between populations of different origin. However, in our
study, the frequency of duplications is in the range of
previous reports, with frequencies of 8% in French [4]
and Japanese AD-families [12], and at 2.7% in Dutch
familial AD-cases [9].
T h ed u p l i c a t i o na tc h r o m o s o m e2 1w er e p o r t e di s
restricted to a maximum size of 1.09 Mb and to a mini-
mum size of 1.01 Mb, which includes the genes for
MRLP39, JAM2, ATP5J, GABPA, APP,a n dCYYR1.A l l
but two of the reported APP-duplications are of different
sizes, and thereby include different genes. From the
reports of different-sized duplications, it has also been
GDB:196999 (APP-dint) GDB:188463 (D21S265)
a)b )
D07
D08
D09
Tri21
Sample
bp bp
Figure 1 Electropherograms of microsatellite markers for three different DNA, (D07-D09), and for trisomy 21-DNA control (T21).O n
the y-axis is peak height and on the x-axis is the marker size in base-pairs. Marker alleles show up as major peaks and indicated in boxes
underneath each allele are size in base-pair and the peak-area. a) Four individual electropherograms showing representative amplification of
marker GDB:196999 (APP-dint). The blue peaks, for alleles 178 and 189, show the suspected copy-number variation in DNA sample D08. b) Four
individual electrographs showing representative amplification of marker GDB:188463 (D21S265).
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feature that serves as a recombination substrate, but that
the APP locus may be a hotspot region for recombination
due to multiple low copy repeats [9]. This is supported by
our finding in a Swedish patient, since it adds a novel-
sized duplication. It has been suggested that sequencing
of the duplication break-points may shed further light on
the molecular basis of the recombination in the region.
The two different-sized duplications found in Dutch
families contain only the APP gene which strongly sug-
gests that APP duplication is the only requirement for
causing AD. The clinical characteristics in patient with
APP-duplications are typically early-onset dementia, cer-
ebral amyloid angiopathy (CAA) and intracerebral
hemorrhage (ICH). When looking within families there
are phenotypes of seizure and dementia with Lewy-
bodies [8-10,26], but clearly these are not found in all
diseased individuals. Rather, intra-familial diversity is
Figure 2 Bar graph showing copy-number from the copy-number assay targeting APP exons (top) and genes flanking APP gene
(lower). On the y-axis is the copy-number calculated relative to trisomy 21-DNA control, and on the x-axis are three patient DNA samples, D07,
D08, D09 and the trisomy-21 DNA (Tri21). For top graph, three different assays at the APP locus were used, positioned in Exon1, (blue), Exon7
(red), and in Exon17 (yellow).). For lower graph, four different assays were used targeting the genes of; MIR155HG, (blue), ATP5J (red), CYYR1
(yellow), and ADAMTS1 (light blue). Assays were performed in tetraplicate and bars are shown as mean ±standard deviation.
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proband III:2, (DNA sample D08), there was an early
onset at 55 years in the cousin (III:4) (Figure 4). Indivi-
dual III:4 had a medical history of syncope and a diagno-
sis of subcortical dementia. Similarly, the history of
individual II:5 also contained remarks of syncope, as well
as vertigo and the diagnosis of multi-infarct dementia.
Individual II:4 had a history of mental illness and was
hospitalized under the diagnosis of schizophrenia and
psychosis. The duplication has only been confirmed in
p r o b a n dI I I : 2 ,s i n c et h e r ea r en oa v a i l a b l eD N As a m p l e s
from other affected family members.
Conclusions
To conclude, we report the first Swedish EO-AD patient
carrying an APP-duplication. We have successfully used
the copy-number assay, showing that it is reliable and
straightforward to use. It is also a good complement to
the use of microsatellites to determine copy-number
since these require the presence of heterozygous mar-
kers to be informative. We would like to emphasize the
value of continued screening for APP-duplications in the
Minimal region: 25 957 532 - 26 971 366  (1,01 Mb) 
Maximal region: 25 950 727 - 27043 885  (1,09 Mb)
Figure 3 Plot from array-CGH made with DNA analytics software.O nt h ey- a x i si st h el o g
2 ratio signal intensity between Cy3-labeled
sample D08 and Cy5-labeled diploid control DNA. The x-axis shows the genomic position of annotated genes (Build 36.1). The colored dots
indicate the signal intensity from hybridization of the patient DNA D08 compared to the signal of the control sample. Equal signal is shown as
black dots, a stronger signal as red dots, and green dots when the signal is weaker from hybridizing with the patient DNA D08. Illustrated as a
brown box is the construction of the maximal region between coordinates 25 950727 - 27 043885 that is duplicated in patient sample D08.
Coordinates for both maximal and minimal region of duplication as determined by array-CGH are given above the plot.
III:1
onset 60
death 74
AD
II:1 II:2
onset 40
death 42
mental illness
I:1
death 70
I:2
death 59
II:3
onset 53
death 73
MID
syncope 
vertigo
II:4
III:2
onset 55
death 63
subcortical dementia
syncope
Figure 4 Pedigree from the duplication family to which patient
D08 (III:1) belongs. Black box indicates dementia diagnosis,
crossed box indicates deceased individual. Given below family
members are age of onset, age of death, and clinical observations.
Abbreviations used are AD for Alzheimer disease, and MID for multi-
infarct dementia.
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Page 7 of 9Swedish population of EO-AD, since we found it to be
more frequent than nucleotide sequence variations in
our cohort of patients referred for genetic mutation
screening.
Additional material
Additional file 1: Table showing classification of the 22 cases of AD
according to their family history with table legend.
Additional file 2: Schematic picture of the APP locus with
surrounding genes with figure legend.
Additional file 3: Table showing nucleotide variations found in the
22 DNA samples for sequencing of APP, PSEN1, and PSEN2 with
table legend.
Additional file 4: Method and result of on In-silico analysis of
nucleotide variation IVS6 +9 and.
Acknowledgements
We are grateful for the contribution made from patients and their families
to this study. This work was supported financially by the Knut and Alice
Wallenberg Foundation, the Swedish Alzheimer Foundation, the Marianne
and Marcus Wallenberg Foundation, the Swedish Research Council, the
Swedish Brain Power network, the King Gustaf V and Queen Victorias
Foundation of Freemasons, the Old Servants foundation, the Stohnes
Foundation and the Regional Agreement on Medical Training and Clinical
research (ALF) between Stockholm County Council and the Karolinska
Institute.
We thank Muhammad-Al-Mustafa Ismail for copy-editing the manuscript.
Author details
1Genetics Unit, Dept of Geriatric Medicine, Karolinska University Hospital,
Huddinge, Sweden.
2Department of Molecular Medicine and Surgery and
Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
3Cancer Cytogenetic Unit, University Hospital of Lausanne, Switzerland.
4Department of Pathology, Karolinska University Hospital, Huddinge, Sweden.
5Department of Neurobiology, Care Sciences and Society (NVS), Karolinska
Institutet, KI-Alzheimer Disease Research Center, Stockholm, Sweden.
Authors’ contributions
HT carried out the molecular genetic studies and made the in-silico analysis.
JS carried out the genome hybridization study. MF and JB carried out the
genealogy of the patients as genetic counselors. IN judged clinical data and
carried out neuropathology. CG was responsible for referral of patients to
mutation screening and conceived the study. HT drafted the manuscript and
HT, JS, MF, JB, IN, and CG contributed to writing the manuscript. All authors
read and approved the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 June 2011 Accepted: 1 November 2011
Published: 1 November 2011
References
1. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L,
Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K,
Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M,
Owen M, Hardy J: Segregation of a missense mutation in the amyloid
precursor protein gene with familial Alzheimer’s disease. Nature 1991,
349(6311):704-706.
2. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H,
Lin C, Li G, Holman K Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP,
Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A,
Sanseau P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, Perkicak-Vance MA,
Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH: Cloning
of a gene bearing missense mutations in early-onset familial Alzheimer’s
disease. Nature 1995, 375(6534):754-760.
3. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH,
Yu CE, Jondro PD, Schmidt SD, Wang K, Crowley A, Fu Y-H, Guenette S,
Galas D, Nemens E, Wijsman E, Bird T, Schellenberg G, Tanzi R: Candidate
gene for the chromosome 1 familial Alzheimer’s disease locus. Science
1995, 269(5226):973-977.
4. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A,
Dumanchin C, Feuillette S, Brice A, Vercelletto M, Vercelletto M, Dubas F,
Frebourg T, Campion D: APP locus duplication causes autosomal
dominant early-onset Alzheimer disease with cerebral amyloid
angiopathy. Nat Genet 2006, 38(1):24-26.
5. Glenner GG, Wong CW: Alzheimer’s disease: initial report of the
purification and characterization of a novel cerebrovascular amyloid
protein. Biochem Biophys Res Commun 1984, 120(3):885-890.
6. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A:
Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s
disease: the CERAD experience, Part XV. Neurology 1996, 46(6):1592-1596.
7. Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R,
Hockey A, Montgomery P, Beyreuther K, Masters CL: Amyloid A4 protein
and its precursor in Down’s syndrome and Alzheimer’s disease. N Engl J
Med 1989, 320(22):1446-1452.
8. Guyant-Marechal I, Berger E, Laquerriere A, Rovelet-Lecrux A, Viennet G,
Frebourg T, Rumbach L, Campion D, Hannequin D: Intrafamilial diversity of
phenotype associated with app duplication. Neurology 2008,
71(23):1925-1926.
9. Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-
Favero J, Cruts M, van Duijn CM, Van Broeckhoven C: APP duplication is
sufficient to cause early onset Alzheimer’s dementia with cerebral
amyloid angiopathy. Brain 2006, 129(Pt 11):2977-2983.
10. Rovelet-Lecrux A, Frebourg T, Tuominen H, Majamaa K, Campion D,
Remes AM: APP locus duplication in a Finnish family with dementia and
intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2007,
78(10):1158-1159.
11. McNaughton D, Knight W, Guerreiro R, Ryan N, Lowe J, Poulter M,
Nicholl DJ, Hardy J, Revesz T, Lowe J, Rossor M, Collinge J, Mead S:
Duplication of amyloid precursor protein (APP), but not prion protein
(PRNP) gene is a significant cause of early onset dementia in a large UK
series. Neurobiol Aging 2010.
12. Kasuga K, Shimohata T, Nishimura A, Shiga A, Mizuguchi T, Tokunaga J,
Ohno T, Miyashita A, Kuwano R, Matsumoto N, Onodera O, Nishizawa M,
Ikeuchi T: Identification of independent APP locus duplication in
Japanese patients with early-onset Alzheimer disease. J Neurol Neurosurg
Psychiatry 2009, 80(9):1050-1052.
13. Blom ES, Viswanathan J, Kilander L, Helisalmi S, Soininen H, Lannfelt L,
Ingelsson M, Glaser A, Hiltunen M: Low prevalence of APP duplications in
Swedish and Finnish patients with early-onset Alzheimer’s disease. Eur J
Hum Genet 2008, 16(2):171-175.
14. Shinde D, Lai Y, Sun F, Arnheim N: Taq DNA polymerase slippage
mutation rates measured by PCR and quasi-likelihood analysis: (CA/GT)n
and (A/T)n microsatellites. Nucleic Acids Res 2003, 31(3):974-980.
15. Raux G, Guyant-Marechal L, Martin C, Bou J, Penet C, Brice A, Hannequin D,
Frebourg T, Campion D: Molecular diagnosis of autosomal dominant
early onset Alzheimer’s disease: an update. J Med Genet 2005,
42(10):793-795.
16. Zekanowski C, Styczynska M, Peplonska B, Gabryelewicz T, Religa D,
Ilkowski J, Kijanowska-Haladyna B, Kotapka-Minc S, Mikkelsen S, Pfeffer A,
Barczak A, Łuczywek E, Wasiak B, Chodakowska-Zebrowska M, Gustaw K,
Łaczkowski J, Sobów T, Kuźnicki J, Barcikowska M: Mutations in presenilin
1, presenilin 2 and amyloid precursor protein genes in patients with
early-onset Alzheimer’s disease in Poland. Exp Neurol 2003,
184(2):991-996.
17. Arango D, Cruts M, Torres O, Backhovens H, Serrano ML, Villareal E,
Montanes P, Matallana D, Cano C, Van Broeckhoven C, Jacquier M:
Systematic genetic study of Alzheimer disease in Latin America:
mutation frequencies of the amyloid beta precursor protein and
presenilin genes in Colombia. Am J Med Genet 2001, 103(2):138-143.
18. Lleo A, Blesa R, Queralt R, Ezquerra M, Molinuevo JL, Pena-Casanova J,
Rojo A, Oliva R: Frequency of mutations in the presenilin and amyloid
precursor protein genes in early-onset Alzheimer disease in Spain. Arch
Neurol 2002, 59(11):1759-1763.
Thonberg et al. BMC Research Notes 2011, 4:476
http://www.biomedcentral.com/1756-0500/4/476
Page 8 of 919. Avramopoulos D: Genetics of Alzheimer’s disease: recent advances.
Genome Med 2009, 1(3):34.
20. Clark R, Hutton M, Fuldner R, Froelich S, Karran E, Talbot C, Crook R: The
structure of the presenilin 1 (S182) gene and identification of six novel
mutations in early onset AD families. Alzheimer’s Disease Collaborative
Group. Nat Genet 1995, 11(2):219-222.
21. Forsell C, Froelich S, Axelman K, Vestling M, Cowburn RF, Lilius L,
Johnston JA, Engvall B, Johansson K, Dahlkild A, Ingelson M, St George-
Hyslop PH, Lannfelt L: A novel pathogenic mutation (Leu262Phe) found
in the presenilin 1 gene in early-onset Alzheimer’s disease. Neurosci Lett
1997, 234(1):3-6.
22. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L:
A pathogenic mutation for probable Alzheimer’s disease in the APP
gene at the N-terminus of beta-amyloid. Nat Genet 1992, 1(5):345-347.
23. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K,
Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Näslund J,
Lannfelt L: The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease
by enhanced Abeta protofibril formation. Nat Neurosci 2001, 4(9):887-893.
24. Forsell C, Matilla K, Axelman K, Lannfelt L: The Arg269His and Glu318Gly
mutations in the presenilin-1 gene found in Swedish early-onset
Alzheimer’s disease families. Sixth International Conference on Alzheimer’s
Disease and Related Disorders, Amsterdam 1998, 18-23, Juli.
25. Keller L, Welander H, Chiang HH, Tjernberg LO, Nennesmo I, Wallin AK,
Graff C: The PSEN1 I143T mutation in a Swedish family with Alzheimer’s
disease: clinical report and quantification of Abeta in different brain
regions. Eur J Hum Genet 2010, 18(11):1202-1208.
26. Cabrejo L, Guyant-Marechal L, Laquerriere A, Vercelletto M, De la
Fourniere F, Thomas-Anterion C, Verny C, Letournel F, Pasquier F, Vital A:
Phenotype associated with APP duplication in five families. Brain 2006,
129(Pt 11):2966-2976.
doi:10.1186/1756-0500-4-476
Cite this article as: Thonberg et al.: Mutation screening of patients with
Alzheimer disease identifies APP locus duplication in a Swedish patient.
BMC Research Notes 2011 4:476.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Thonberg et al. BMC Research Notes 2011, 4:476
http://www.biomedcentral.com/1756-0500/4/476
Page 9 of 9